OTCMKTS:IDRSF

Idorsia (IDRSF) Stock Forecast, Price & News

$2.70

-0.30 (-10.00%)

(As of 09/28/2023 ET)

Compare

Today's Range: $2.70
▼
$2.70
50-Day Range: $2.70
▼
$8.00
52-Week Range: $2.70
▼
$19.14

Volume: 1,800 shs
Average Volume: 2,451 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Analyst Ratings Chart Competitors Headlines Short Interest

About Idorsia (OTCMKTS:IDRSF) Stock

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

IDRSF Price History

30 days | 90 days | 365 days | Advanced Chart

IDRSF Stock News Headlines

September 19, 2023 | americanbankingnews.com

Idorsia Ltd (OTCMKTS:IDRSF) Given Average Recommendation of "Strong Sell" by Analysts

September 15, 2023 | msn.com

NICE recommends Idorsia’s chronic insomnia treatment for UK patients

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

September 6, 2023 | uk.finance.yahoo.com

Idorsia reacquires the world-wide rights to aprocitentan

August 31, 2023 | finance.yahoo.com

Tausif ('Tosh') Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager

August 25, 2023 | finance.yahoo.com

Idorsia Ltd (IDIA.SW)

August 18, 2023 | uk.finance.yahoo.com

Are Investors Undervaluing Idorsia Ltd (VTX:IDIA) By 38%?

July 27, 2023 | msn.com

Idorsia: Restructuring In Place

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

July 27, 2023 | finance.yahoo.com

Analysts Have Just Cut Their Idorsia Ltd (VTX:IDIA) Revenue Estimates By 21%

July 25, 2023 | finance.yahoo.com

Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value

July 25, 2023 | marketwatch.com

Idorsia Shares Plunge After Suspension of 2025 Profitability Target

July 21, 2023 | finance.yahoo.com

Idorsia announces a cost reduction initiative to be implemented by the end of 2023

July 20, 2023 | jp.reuters.com

UPDATE 2-Japan's Sosei buys Idorsia Pharma's Japan, Korea units for $466 mln

July 20, 2023 | benzinga.com

Sosei Heptares - Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia

July 10, 2023 | finance.yahoo.com

Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS

June 25, 2023 | finanznachrichten.de

Idorsia Pharmaceuticals Ltd: New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2023

June 20, 2023 | finance.yahoo.com

Idorsia has secured bridge financing in the amount of CHF 75 million

June 10, 2023 | msn.com

Idorsia: Dilution Risk Causes Downgrade To Hold

June 6, 2023 | bizjournals.com

Idorsia in talks about potential $440M Asia Pacific licensing deal

June 2, 2023 | finance.yahoo.com

Investors in Idorsia (VTX:IDIA) have unfortunately lost 71% over the last three years

May 30, 2023 | finance.yahoo.com

Idorsia announces a change to commercial leadership

May 11, 2023 | msn.com

Idorsia (SIX:IDIA) Price Target Decreased by 7.89% to 14.26

May 7, 2023 | finance.yahoo.com

Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia

May 6, 2023 | uk.finance.yahoo.com

Getting In Cheap On Idorsia Ltd (VTX:IDIA) Might Be Difficult

April 18, 2023 | uk.finance.yahoo.com

Invitation to Idorsia's Q1 2023 Financial Results webcast and conference call

April 9, 2023 | bizjournals.com

Idorsia Pharmaceuticals files citizens petition with DEA seeking to de-schedule its insomnia drug Quviviq

See More Headlines

Receive IDRSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:IDRSF
CUSIP: N/A
CIK: N/A
Web: www.idorsia.com
Phone: (158) 844-0000
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Jean-Paul Clozel M.D. (Age 68)
CEO & Exec. Director
Comp: $1.53M

Mr. André C. Muller (Age 60)
Exec. VP & CFO

Dr. Martine Clozel (Age 68)
Exec. VP & Chief Scientific Officer

Mr. Andrew C. Weiss (Age 55)
Sr. VP and Head of Investor Relations & Corp. Communications

Mr. Julien Gander L.L.M. (Age 44)
Sr. VP, Group Gen. Counsel & Company Sec.

Mr. Alexander Khatuntsev (Age 45)
Sr. VP & Head of Global HR

Dr. Guy Braunstein M.D. (Age 67)
Exec. VP & Chief Medical Officer

Mr. Olivier Lambert (Age 57)
Sr. VP and Head of Global Pharmaceutical Devel. & Quality Assurance

Mr. Markus A. Riederer (Age 61)
Sr. VP & Head of Drug Discovery Biology

Mr. Christoph Boss (Age 55)
Sr. VP & Head of Drug Discovery Chemistry

Key Competitors

View All Competitors

IDRSF Stock - Frequently Asked Questions

Should I buy or sell Idorsia stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last year. There are currently 4 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "strong sell" IDRSF shares.
View IDRSF analyst ratings or view top-rated stocks.
How have IDRSF shares performed in 2023?: Idorsia's stock was trading at $14.69 at the beginning of the year. Since then, IDRSF stock has decreased by 81.6% and is now trading at $2.70.
View the best growth stocks for 2023 here.
Are investors shorting Idorsia?: Idorsia saw a increase in short interest in August. As of August 31st, there was short interest totaling 10,313,000 shares, an increase of 9.7% from the August 15th total of 9,401,800 shares. Based on an average trading volume of 1,300 shares, the short-interest ratio is presently 7,933.1 days.
View Idorsia's Short Interest.

What is Idorsia's stock symbol?: Idorsia trades on the OTCMKTS under the ticker symbol "IDRSF."
How do I buy shares of Idorsia?: Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Idorsia's stock price today?: One share of IDRSF stock can currently be purchased for approximately $2.70.
How can I contact Idorsia?: Idorsia's mailing address is Hegenheimermattweg 91, Allschwil, Basel-Landschaft (Basle. The official website for the company is www.idorsia.com. The company can be reached via phone at (158) 844-0000.

This page (OTCMKTS:IDRSF) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial